热门资讯> 正文
Viridian疗法称REVEAL-1研究符合甲状腺眼科疾病每四周一次（Q4 W）的前凸反应率的主要终点
2026-03-30 19:16
- REVEAL-1 met the primary endpoint of Q4W proptosis responder rate (PRR) with a highly statistically significant treatment effect.
- Elegrobart Q4W and Q8W achieved clinically meaningful 54% and 63% PRR versus 18% placebo at week 24.
- Complete resolution of diplopia in 51% of patients treated Q4W versus 16% placebo at week 24.
- Elegrobart was generally well tolerated in both dose groups with low rates of hearing impairment.
- REVEAL-2, a phase 3 clinical trial evaluating elegrobart in patients with chronic TED, is on track for topline readout in Q2 2026; BLA submission anticipated in Q1 2027.
- Viridian ended Q4 2025 with $875 million in cash; the company anticipates existing cash, potential near-term milestones from its 2025 royalty agreement, and anticipated commercial revenues from veligrotug and elegrobart if approved, to fund current business plans through profitability.
推荐文章
提价83%需求却暴增400%！智谱、MiniMax锁定大模型定价权，AI Agent元年即将开启？
港股见底了吗？北水大举加仓逾600亿港元！大行看好4月做多窗口来临，十大金股一图睇全
华盛早报 | 伊朗与阿曼拟共管霍尔木兹！美股V型反转；伊朗袭击甲骨文、亚马逊数据中心；港美股今日因假期休市一天
诺和诺德称：口服版Wegovy减肥效果优于礼来GLP‑1口服药
美股机会日报 | 特朗普粉碎停战幻想！恐慌指数飙升12%，纳指期货跌约2%；美油期货暴涨超9%！油气股飙升，美国原油基金ETF涨超9%
清明休市提醒 | 港股本周五休市，下周三恢复交易；美股周五休市一天
油价上涨 此前特朗普表示伊朗冲突可能在未来几周升级
野村：特朗普讲话未能发出局势降温的明确信号
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
